Retinal Cell Transplantation Tolerance and Rejection

视网膜细胞移植耐受和排斥

基本信息

  • 批准号:
    7235606
  • 负责人:
  • 金额:
    $ 31.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-07-01 至 2010-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is a major cause of blindness in the United States. Replacement of dead or damaged cells with healthy retinal cells is a very promising approach to the treatment of this, and other, retinal diseases. Our long-term goal is to develop the methods for transplanting retinal pigment epithelial (RPE) cells early in the course of AMD to rescue photoreceptor cells. The central hypothesis of this proposal is that the identification of the immunological mechanisms, which are responsible for RPE transplant rejection, will provide therapeutic targets for inducing long-term graft acceptance. The role of CD4+ and CD8+ T cells in rejection will be tested by adoptively transferring them into immunodeficient, recombinase (Rag-1) knockout mice before transplantation of allogeneic RPE. The relative contribution of major and minor histocompatibility antigens to RPE rejection will be assessed using recombinant, inbred strains of mice. The mechanisms by which RPE grafts are rejected will be determined using T cell receptor (TCR) transgenic mice and RPE expressing defined transplantation antigens. Activation and proliferation of adoptively transferred TCR transgenic T cells will be tracked in lymph nodes and the eyes of transplant recipients. TCR T cells recovered from the eyes will be analyzed for various functional activities. Finally, the hypothesis that allograft-specific tolerance can prolong survival of RPE in the absence of continuous treatment with immunosuppressive agents will be tested. Results from these studies should identify strategies to prevent rejection that can be tested in preclinical models of RPE transplantation.
描述(由申请人提供):年龄相关性黄斑变性(AMD)是美国失明的主要原因。用健康的视网膜细胞替代死亡或受损的细胞是治疗这种疾病和其他视网膜疾病的一种非常有前途的方法。我们的长期目标是开发在AMD早期移植视网膜色素上皮细胞(RPE)的方法来拯救光感受器细胞。该建议的中心假设是,确定导致RPE移植排斥反应的免疫机制,将为诱导长期移植接受提供治疗靶点。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JUDITH A KAPP其他文献

JUDITH A KAPP的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JUDITH A KAPP', 18)}}的其他基金

Retinal Cell Transplantation Tolerance and Rejection
视网膜细胞移植耐受和排斥
  • 批准号:
    7068479
  • 财政年份:
    2004
  • 资助金额:
    $ 31.68万
  • 项目类别:
Retinal Cell Transplantation Tolerance and Rejection
视网膜细胞移植耐受和排斥
  • 批准号:
    6912734
  • 财政年份:
    2004
  • 资助金额:
    $ 31.68万
  • 项目类别:
Retinal Cell Transplantation Tolerance and Rejection
视网膜细胞移植耐受和排斥
  • 批准号:
    6789520
  • 财政年份:
    2004
  • 资助金额:
    $ 31.68万
  • 项目类别:
Regulation of Ocular Tolerance by Gamma/delta T Cells
γ/δ T 细胞对眼耐受性的调节
  • 批准号:
    6635735
  • 财政年份:
    2001
  • 资助金额:
    $ 31.68万
  • 项目类别:
Regulation of Ocular Tolerance by Gamma/delta T Cells
γ/δ T 细胞对眼耐受性的调节
  • 批准号:
    6318736
  • 财政年份:
    2001
  • 资助金额:
    $ 31.68万
  • 项目类别:
Regulation of Ocular Tolerance by Gamma/delta T Cells
γ/δ T 细胞对眼耐受性的调节
  • 批准号:
    6518724
  • 财政年份:
    2001
  • 资助金额:
    $ 31.68万
  • 项目类别:
Regulation of Ocular Tolerance by Gamma/delta T Cells
γ/δ T 细胞对眼耐受性的调节
  • 批准号:
    6896318
  • 财政年份:
    2001
  • 资助金额:
    $ 31.68万
  • 项目类别:
GAMMA/DELTA T CELLS IN TOLERANCE AND TUMOR IMMUNITY
GAMMA/Delta T 细胞在耐受性和肿瘤免疫方面的作用
  • 批准号:
    6376248
  • 财政年份:
    1996
  • 资助金额:
    $ 31.68万
  • 项目类别:
GAMMA/DELTA T CELLS IN TOLERANCE AND TUMOR IMMUNITY
GAMMA/Delta T 细胞在耐受性和肿瘤免疫方面的作用
  • 批准号:
    2114274
  • 财政年份:
    1996
  • 资助金额:
    $ 31.68万
  • 项目类别:
GAMMA/DELTA T CELLS IN TOLERANCE AND TUMOR IMMUNITY
GAMMA/Delta T 细胞在耐受性和肿瘤免疫方面的作用
  • 批准号:
    2700672
  • 财政年份:
    1996
  • 资助金额:
    $ 31.68万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 31.68万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了